• multiple myeloma - 2nd line (L2) 1
• myofibroblastic tumors
• neurofibroma
• neutropenia
• osteosarcoma
• ovarian cancer (OC) 9

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• avelumab plus pegylated liposomal doxorubicin
• avelumab plus SoC
• Immune checkpoint association
• nivolumab plus ipilimumab
• poly ADP-ribose polymerase (PARP) inhibitor
• niraparib
• olaparib
• rucaparib
• target therapy
• multikinase inhibitor
• nintedanib

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs anthracyclines
• vs doxorubicin
• vs pegylated liposomal doxorubicin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone

  All patients Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) stage III (locally advanced) stage IV (metastatic)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

ovarian cancer (OC), anti-PD-(L)1 vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;